Health Economics›Hepatocellular carcinoma›Local therapy for advanced disease

Local therapy for advanced disease

Hepatocellular carcinoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Axitinib and TACE Variant #01	—	R 42 804	56d	—	—	—	—	—
Lenvatinib and TACE Variant #01	—	R 24 831	28d	—	17.8 mo	—	—	1
FOLFOX-HAIC and Sorafenib Variant #01	—	R 18 258	21d	—	13.4 mo	—	—	1
FOLFOX-HAIC Variant #01	—	R 2 256	35d	—	23.1 mo	—	—	1
TACE, then 5-FU Variant #01	—	R 1 140	60d	—	—	—	—	—
DEB-TACE Variant #01 Partial	—	—	—	5.2 mo	18.9 mo	—	—	3
Radioembolization Variant #01 Partial	—	—	—	—	8.4 mo	—	—	2
TACE monotherapy Variant #01 Partial	—	—	—	8.2 mo	26.1 mo	—	—	8
DEB-TACE and Apatinib Variant #01 Partial	—	—	—	7.1 mo	23.3 mo	—	—	2

9 of 9 regimens shown